NEW YORK – Achilles Therapeutics said on Friday that after reviewing interim data from the company's Phase I/IIb Chiron and Thetis clinical trials, an independent data and safety monitoring committee has recommended that both trials continue as planned.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account? Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account? Register for Free.
This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.